Table 1.
Treatment | Dose | Avg. no. colonies per treatment
|
|
---|---|---|---|
Erythroid colonies | GM colonies | ||
None | — | 0 ± 0 | 86 ± 13 |
DMSO | 0.4% | 0 ± 0 | 74 ± 2 |
EPO | 100 mU/ml | 66 ± 1 | 87 ± 7 |
DMSO + EPO | 100 mU/ml | 55 ± 2 | 73 ± 5 |
30 mU/ml | 48 ± 3 | 73 ± 5 | |
10 mU/ml | 20 ± 7 | 72 ± 13 | |
3 mU/ml | 2 ± 1 | 65 ± 5 | |
Compound 2 | 2000 nM | 0 ± 0 | 65 ± 15 |
500 nM | 0 ± 0 | 66 ± 11 | |
125 nM | 0 ± 0 | 72 ± 11 | |
Compound 5 | 2000 nM | 47 ± 2 | 65 ± 1 |
1000 nM | 43 ± 1 | 76 ± 1 | |
500 nM | 30 ± 2 | 75 ± 5 | |
250 nM | 12 ± 2 | 71 ± 1 | |
125 nM | 3 ± 1 | 75 ± 1 |
Human CD34+ progenitor cells (1.5 × 103/plate) were plated in semisolid media to allow growth of erythroid colonies and GM colonies. Colonies of each type were counted after 12–15 days of seeding under each condition. Data are mean (SEM) of two independent experiments, where each determination was performed in triplicate.